SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently facing intense scrutiny and widespread accusations of being a sophisticated scam, driven by severe community frustration over inaccessible tokens, failed claim processes, and suspicious exchange activity. Investors are actively debating the legitimacy of the project as they vent about missing balances, lack of functional contracts, and concerns that early access programs unfairly privilege insiders over retail participants.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors gear up for the presentation of long-term Phase 3 VELA trial data at the upcoming American Academy of Dermatology (AAD) meeting, which is widely expected to validate sonelokimab as a best-in-class treatment for hidradenitis suppurativa. Community sentiment remains heavily bullish, with active discussions focusing on anticipated institutional accumulation, potential M&A activity involving major pharmaceutical suitors, and the company's path toward BLA submission later this year.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF (SHLD) is trending as investors capitalize on surging global military spending and geopolitical instability, with the community highlighting its strategic exposure to both U.S. giants and international defense leaders. Traders are closely monitoring the ETF's resilience and its concentrated positions in high-growth AI and defense-tech names as a play on long-term sector tailwinds.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is currently capturing significant market attention as traders monitor its price action following recent airdrop activity and major exchange listings, with the community actively debating whether it serves as a legitimate institutional-grade privacy solution or simply another speculative venture. Sentiment remains deeply divided, as some investors express confidence in the project's Cardano-linked utility and zero-knowledge proof technology, while others remain skeptical, citing concerns over decentralization, corporate influence, and perceived parallels to previous market cycles.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as investors weigh persistent geopolitical uncertainty and fiscal policy concerns against the broader strength of U.S. markets. Community discourse remains heavily polarized, with many users debating the impact of ongoing administration conflicts on long-term portfolio stability and the relative merits of broad index-based strategies versus active trading.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is under intense pressure as investors weigh a disappointing Q2 earnings miss against a soft Q3 delivery outlook, fueling a broader sell-off in Chinese EV shares. The community is actively debating the company's competitive standing against peers like NIO, with heightened scrutiny on build quality, recent model performance, and fierce market share battles in the premium SUV segment.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending as investors monitor the upcoming PDUFA date for its Prader-Willi syndrome therapy, VYKAT XR, with significant interest focused on its potential commercial launch and market opportunity. Community discussions are heavily centered on analyzing clinical data, assessing the competitive landscape, and debating the stock's valuation as expectations for regulatory approval continue to drive volatility.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is currently under intense pressure as investors express concerns that its traditional IT consulting and labor-heavy business model is being disrupted by advancements in artificial intelligence. The stock has faced a sustained downtrend as the community debates whether the firm can successfully pivot to automated AI solutions or if it faces long-term obsolescence in an AI-first market.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention due to positive momentum from the proposed Mission 70 tokenomics, which aims to reduce inflation, and growing institutional interest highlighted by sovereign cloud developments in regions like Switzerland and Pakistan. Investors are actively debating the project's long-term potential as a decentralized infrastructure play, with many closely monitoring increased network activity, cycle burn rates, and potential for future mass adoption of on-chain applications.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is facing heightened volatility and a sharp pullback as investors process NASA's strategic pivot toward a moon-base infrastructure model, which has delayed expectations for the Lunar Terrain Vehicle contract. Despite the market reaction, bullish sentiment persists within the community as investors argue the shift fundamentally benefits the company's core surface-logistics expertise and long-term positioning for upcoming space exploration awards.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raphael Pharmaceutical, Inc. is a clinical-stage biotechnology company. It is focused on providing a novel cannabinoid-based research platform for the treatment of inflammatory diseases. The firm’s product candidate, HPC1, is a cannabinoid formulation developed for the treatment of rheumatoid arthritis. The company was founded in May 2007 and is headquartered in Tel Aviv, Israel.

Raphael Pharmaceutical Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

RAPH
Raphael Pharmaceutical Inc

Feed

News

Sentiment

Fundamentals

Info

Latest RAPH News

RAPHRaphael Pharmaceutical Inc